JAK-STAT Pathway Activation in Malignant and Non-Malignant Cells Contributes to MPN Pathogenesis and Therapeutic Response

The identification of JAK2/MPL mutations in patients with myeloproliferative neoplasms (MPN) led to the clinical development of JAK kinase inhibitors, including ruxolitinib. Ruxolitinib reduces splenomegaly and systemic symptoms in myelofibrosis (MF) and improves overall survival; however the mechan...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Discov
Autori principali: Kleppe, Maria, Kwak, Minsuk, Koppikar, Priya, Riester, Markus, Keller, Matthew, Bastian, Lennart, Hricik, Todd, Bhagwat, Neha, McKenney, Anna Sophia, Papalexi, Efthymia, Abdel-Wahab, Omar, Rampal, Raajit, Marubayashi, Sachie, Chen, Jonathan J., Romanet, Vincent, Fridman, Jordan S., Bromberg, Jacqueline, Teruya-Feldstein, Julie, Murakami, Masato, Radimerski, Thomas, Michor, Franziska, Fan, Rong, Levine, Ross L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4355105/
https://ncbi.nlm.nih.gov/pubmed/25572172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0736
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi